{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:01:11Z","timestamp":1792623671147,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02275-5","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:48:27Z","timestamp":1769165307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group"],"prefix":"10.1186","volume":"27","author":[{"given":"Emmanouil V.","family":"Dermitzakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas A.","family":"Argyriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chondrogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Foska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Rikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Athanasopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Tsironis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Soldatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Koutsokera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tsitsaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Litsardopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Mavraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Vikelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"1","key":"2275_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-020-01110-9","volume":"29","author":"L Lombard","year":"2020","unstructured":"Lombard L, Farrar M, Ye W, Kim Y, Cotton S, Buchanan AS, Jackson J, Joshi S (2020) A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to Triptan medication. J Headache Pain 29(1):41.","journal-title":"J Headache Pain"},{"issue":"1","key":"2275_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain 20(1):41.","journal-title":"J Headache Pain"},{"issue":"13","key":"2275_CR3","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/cells13131098","volume":"13","author":"M Tanaka","year":"2024","unstructured":"Tanaka M, Tuka B, V\u00e9csei L (2024) Navigating the neurobiology of migraine: from pathways to potential therapies. Cells 13(13):1098.","journal-title":"Cells"},{"issue":"3","key":"2275_CR4","doi-asserted-by":"publisher","first-page":"e208074","DOI":"10.1212\/WNL.0000000000208074","volume":"102","author":"RE Shapiro","year":"2024","unstructured":"Shapiro RE, Nicholson RA, Seng EK, Buse DC, Reed ML, Zagar AJ, Ashina S, Muenzel EJ, Hutchinson S, Pearlman EM, Lipton RB (2024) Migraine-Related stigma and its relationship to Disability, interictal Burden, and quality of life: results of the OVERCOME (US) study. Neurology 102(3):e208074.","journal-title":"Neurology"},{"issue":"5","key":"2275_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/head.13529","volume":"59","author":"S Iyengar","year":"2019","unstructured":"Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. Headache 59(5):659\u2013681.","journal-title":"Headache"},{"issue":"2","key":"2275_CR6","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103(2):1565\u20131644.","journal-title":"Physiol Rev"},{"issue":"1","key":"2275_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","volume":"18","author":"M Deen","year":"2017","unstructured":"Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltr\u00e1n E, Vigneri S, Edvinsson L, Van Den Maassen A (2017) European headache federation school of advanced studies (EHF-SAS). Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 18(1):96.","journal-title":"J Headache Pain"},{"issue":"1","key":"2275_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6.","journal-title":"J Headache Pain"},{"issue":"3","key":"2275_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW (2019) CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia 39(3):445\u2013458.","journal-title":"Cephalalgia"},{"issue":"10","key":"2275_CR10","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/head.13439","volume":"58","author":"M Levin","year":"2018","unstructured":"Levin M, Silberstein SD, Gilbert R, Lucas S, Munsie L, Garrelts A, Kennedy K, Everman N, Pearlman E (2018) Basic considerations for the use of monoclonal antibodies in migraine. Headache 58(10):1689\u20131696.","journal-title":"Headache"},{"issue":"1","key":"2275_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/jpet.119.264671","volume":"374","author":"LF Garcia-Martinez","year":"2020","unstructured":"Garcia-Martinez LF, Raport CJ, Ojala EW, Dutzar B, Anderson K, Stewart E, Kovacevich B, Baker B, Billgren J, Scalley-Kim M, Karasek C, Allison D, Latham JA (2020) Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin Gene-Related peptide. J Pharmacol Exp Ther 374(1):93\u2013103.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2275_CR12","doi-asserted-by":"publisher","first-page":"e00567","DOI":"10.1002\/prp2.567","volume":"8","author":"B Baker","year":"2020","unstructured":"Baker B, Schaeffler B, Beliveau M, Rubets I, Pederson S, Trinh M, Smith J, Latham J (2020) Population Pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect 8(2):e00567.","journal-title":"Pharmacol Res Perspect"},{"issue":"23","key":"2275_CR13","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, Lindsten A, Mehta L, Cady R (2021) Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: A randomized clinical trial. JAMA 325(23):2348\u20132356.","journal-title":"JAMA"},{"issue":"2","key":"2275_CR14","doi-asserted-by":"publisher","first-page":"11076","DOI":"10.1080\/21655979.2021.2006977","volume":"12","author":"L David","year":"2021","unstructured":"David L, Scalley-Kim M, Olland A, White A, Misura K (2021) The eptinezumab: CGRP complex structure - the role of conformational changes in binding stabilization. Bioengineered 12(2):11076\u201311086.","journal-title":"Bioengineered"},{"key":"2275_CR15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2147\/TCRM.S263824","volume":"19","author":"C Altamura","year":"2023","unstructured":"Altamura C, Brunelli N, Marcosano M, Alesina A, Fofi L, Vernieri F (2023) Eptinezumab for the prevention of migraine: clinical Utility, patient preferences and Selection - A narrative review. Ther Clin Risk Manag 19:959\u2013971.","journal-title":"Ther Clin Risk Manag"},{"key":"2275_CR16","doi-asserted-by":"publisher","first-page":"1355877","DOI":"10.3389\/fneur.2024.1355877","volume":"15","author":"P Irimia","year":"2024","unstructured":"Irimia P, Santos-Lasaosa S, Pozo-Rosich P, Leira R, Pascual J, L\u00e1inez JM (2024) Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. Front Neurol 15:1355877.","journal-title":"Front Neurol"},{"issue":"7","key":"2275_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/head.14737","volume":"64","author":"YJ Zhao","year":"2024","unstructured":"Zhao YJ, Ong JJY, Sonu SK, Dang J, Ng CC, Herr KJ, Bose R, Jion YI (2024) A real-world prospective observational study of eptinezumab in Asian patients with migraine. Headache 64(7):810\u2013824.","journal-title":"Headache"},{"issue":"1","key":"2275_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-024-01788-1","volume":"25","author":"A Scheffler","year":"2024","unstructured":"Scheffler A, Wenzel P, Bendig M, Gendolla A, Basten J, Kleinschnitz C, Nsaka M, Lindner D, Naegel S, Burow P, Fleischmann R, Holle D (2024) Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany. J Headache Pain 25(1):79.","journal-title":"J Headache Pain"},{"issue":"7","key":"2275_CR19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/brainsci14070672","volume":"14","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Orlando B, Egeo G, d\u2019Onofrio F, Doretti A, Messina S et al (2024) Evaluating the Effectiveness, Tolerability, and safety of eptinezumab in High-Frequency and chronic migraine in real world: EMBRACE-The first Italian Multicenter, Prospective, real-Life study. Brain Sci 14(7):672.","journal-title":"Brain Sci"},{"issue":"6","key":"2275_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00415-025-13095-z","volume":"272","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Aurilia C, Egeo G, Doretti A, d\u2019Onofrio F, Scatena P et al (2025) Italian migraine registry (I-GRAINE) study group. A 24-week prospective, multicenter, real-world study on eptinezumab\u2019s effectiveness and safety in migraine prevention (EMBRACE II). J Neurol 272(6):382.","journal-title":"J Neurol"},{"key":"2275_CR21","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"2275_CR22","unstructured":"European Medicines Agency (2025) Summary of Product Characteristics: Eptinezumab (VYEPTI). Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyepti-epar-product-information_en.pdf."},{"issue":"2","key":"2275_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94(2):149\u2013158.","journal-title":"Pain"},{"issue":"2","key":"2275_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.1999.019002107.x","volume":"19","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J (1999) Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 19(2):107\u2013114.","journal-title":"Cephalalgia"},{"issue":"8","key":"2275_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahl\u00f6f CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2013974.","journal-title":"Qual Life Res"},{"issue":"1","key":"2275_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s41669-017-0034-3","volume":"2","author":"T Oikonomidi","year":"2018","unstructured":"Oikonomidi T, Vikelis M, Artemiadis A, Chrousos GP, Darviri C (2018) Reliability and validity of the Greek migraine disability assessment (MIDAS) questionnaire. Pharmacoecon Open 2(1):77\u201385.","journal-title":"Pharmacoecon Open"},{"issue":"5","key":"2275_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol group. Ann Med 33(5):337\u2013343.","journal-title":"Ann Med"},{"issue":"1","key":"2275_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","volume":"27","author":"H Hurst","year":"2004","unstructured":"Hurst H, Bolton J (2004) Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther 27(1):26\u201335.","journal-title":"J Manipulative Physiol Ther"},{"issue":"2","key":"2275_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT et al (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9(2):105\u2013121.","journal-title":"J Pain"},{"issue":"1","key":"2275_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s10194-025-02180-3","volume":"26","author":"AP Andreou","year":"2025","unstructured":"Andreou AP, Hill B, Al-Rawi R, Murphy M, Soares I, Briscoe J, Kilner R, Lambru G (2025) A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience. J Headache Pain 26(1):235.","journal-title":"J Headache Pain"},{"key":"2275_CR31","doi-asserted-by":"publisher","unstructured":"Vikelis M, Rikos D, Argyriou AA, Dermitzakis EV, Andreou AP, Russo A (2025) Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis. Expert Rev Neurother 1\u201316. https:\/\/doi.org\/10.1080\/14737175.2025.2461766.","DOI":"10.1080\/14737175.2025.2461766"},{"issue":"8","key":"2275_CR32","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/03331024221077646","volume":"42","author":"M Ashina","year":"2022","unstructured":"Ashina M, McAllister P, Cady R, Hirman J, Ettrup A (2022) Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: post hoc analysis of PROMISE-1 and PROMISE-2. Cephalalgia 42(8):696\u2013704.","journal-title":"Cephalalgia"},{"issue":"5","key":"2275_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/00207454.2022.2115906","volume":"134","author":"H Chen","year":"2024","unstructured":"Chen H, Luo W (2024) Efficacy and safety of eptinezumab 300\u00a0mg versus 100\u00a0mg for migraine patients: a meta-analysis of randomized controlled studies. Int J Neurosci 134(5):462\u2013467.","journal-title":"Int J Neurosci"},{"issue":"1","key":"2275_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s10194-022-01507-8","volume":"23","author":"AP Andreou","year":"2022","unstructured":"Andreou AP, Fuccaro M, Hill B, Murphy M, Caponnetto V, Kilner R, Lambru G (2022) Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis. J Headache Pain 23(1):139.","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02275-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02275-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02275-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:00:20Z","timestamp":1771423220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02275-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2275"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02275-5","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of General Clinic, Thessaloniki and \u201cAgios Andreas\u201d Patras Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants completed an informed consent process and signed informed consent forms approved by the Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}